Health & Environmental Research Online (HERO)


Print Feedback Export to File
7109032 
Journal Article 
Hit and lead criteria in drug discovery for infectious diseases of the developing world 
Katsuno, Kei; Slingsby, BT; Burrows, JN; Duncan, Ken; van Huijsduijnen, RobH; Kaneko, T; Kita, K; Mowbray, CE; Schmatz, D; Warner, P; , 
2015 
1 
Nature Reviews. Drug Discovery
ISSN: 1474-1776
EISSN: 1474-1784 
NATURE PUBLISHING GROUP 
LONDON 
751-758 
26435527 
WOS:000364272600014 
Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishnnaniasis and Chagas disease. Here, we present the agreed criteria and discuss the underlying rationale.